Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:134636.
doi: 10.1155/2012/134636. Epub 2012 Sep 13.

Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis

Lei Liu  1 , Fiona Cuthbertson
Affiliations

Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis

Lei Liu et al. Case Rep Med. 2012.

Abstract

We report a case of fingolimod-associated bilateral cystoid macular oedema in a patient with multiple sclerosis (MS). A 34-year-old female, diagnosed with MS at age of 30, developed bilateral blurred vision 5 days after initiation of fingolimod. She was misdiagnosed as optic neuritis initially and fingolimod was only discontinued 3 weeks after onset of her visual symptoms when OCT showed prominent bilateral cystoid macular oedema and subretinal fluid. Although her left corrected vision returned to 6/6, she had persistently decreased right visual acuity of 6/12 after 5 months. This paper aims to raise awareness among ophthalmologists and neurologists of the importance of early recognition of macular oedema associated with fingolimod.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Bilateral cystoid macular oedema was prominent with subretinal fluid at 20 days after initiation of fingolimod. Right eye was worse compared with left eye.
Figure 2
Figure 2
Cystoid macular oedema was resolving after 3 months with minimal subretinal fluid in left eye, although right macular oedema was still significant.
Figure 3
Figure 3
Left macular oedema completely resolved while there was mild residual oedema in right macular after 5 months.
See this image and copyright information in PMC

References

    1. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. European Journal of Neurology. 2006;13(7):700–722. - PubMed
    1. Nakahara J, Maeda M, Aiso S, Suzuki N. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clinical Reviews in Allergy and Immunology. 2012;42(1):26–34. - PubMed
    1. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clinical Neuropharmacology. 2010;33(2):91–101. - PMC - PubMed
    1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. The New England Journal of Medicine. 2010;362(5):402–415. - PubMed
    1. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. The New England Journal of Medicine. 2010;362(5):387–401. - PubMed

LinkOut - more resources